Aeolus Pharmaceuticals (AOLS)

[mick]

https://www.barchart.com/stocks/quotes/Aols/opinion

[mick]

you still doing this one \\\\\///// Aeolus Pharmaceutica (AOLS)
0.0012 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
0.0001 0.0012 - - -
AOLS Detailed Quote

[Werbe]

I think its Gerald...

[GetSeriousOK]

Who is buying this dead ticker? That's insane.

Here is some fun reading about AOLS:

https://www.whitesecuritieslaw.com/2018/09/20/aeolus-pharmaceuticals/

Of course, the White Law Group can't help the insane person who's buying it now, but maybe there are some bagholders from 2017 out there who could benefit.

[Werbe]

hello $AOLS

[cameron86]

Volume....

[Werbe]

Werbe, Greek gods!!!

[Werbe]

Not myself but Bid support @ 11s

Bid
0.0011

Ask
0.0016

B/A Size
1000000x10000

[Werbe]

Right, my sarcasm is hard to follow sometimes..

See, there are 2 websites up for AOLS.. You were saying the old one was down, which it is. It gives a cannot be reached message. http://www.aolsrx.com/

There is another website that seems 2 have been working all along but fell out of maintenance. It now shows a COMING SOON message. Now, in penny world that is something 2 work on. Especially when this ticker has regular baggage like most others do, but has an awesome share structure and a low market cap of 288k. Money can be made here regardless IMO. Bid support has been holding it here also, so lets see what plays out.

Also, if u have info 2 show whats been sold off etc show please.. I cannot find anything and until then I keep an open mind.

BTW, sorry 4 saying u were posting wrong info. My bad, I was being petty.

[GetSeriousOK]

OK i'm taking my own personal waybackmachine journey through the past year of posts just to refresh my memory of why I stopped caring about AOLS:

post #683: They don't own the patents. They were licensing the patents. Looks like assets are about $700,000 and liabilities are about $700,000 or higher, depending on how much cash they burned in 2018 leading up to their decision to throw in the towel.

post #686: the ticker symbol is an asset only if the new owners cancel the existing shares.

post #693: May 2nd 2018, I commented that http://www.aeoluspharma.com/ was just an outline, and none of the links worked, and http://www.aolsrx.com/ was a 404 not found.

post #708, "the website is gone:" no idea why I posted that on that day. Maybe it was down that day.

[GetSeriousOK]

I am going by Waybackmachine and I see same info on site I linked as from March and July and up until October of this year.

I don't remember the exact date the website disappeared -- I noticed it in July but the ticker died in March when they assigned all assets to the lawyer and told him to LIQUIDATE. They left one framework outline page on the Aeolus URL but if you clicked on any link, you got a 404 Not Found. That's what "the website is gone" means. There was a dummy page still up in the root, but the web SITE was gone.

click on one of the hotlinks on that dummy Aeolus web page you found in your waybackmachine from March to October -- you'll see what I mean.

PR shows they went outside of court system. That would be called BANKRUPTCY?

Bankruptcies go through the court system -- Filing for BK means filing for Chapter 7 or 11 or 13 protection. Aeolus did not file for bankruptcy -- they simply made an agreement with the creditors -- the cheapest possible way to end it. Aeolus threw in the towel and had an attorney LIQUIDATE all assets.

There are no assets left over. The lawyer didn't keep some and liquidate some. the lawyer LIQUIDATED ALL ASSETS. There is nothing to spin off.

The IP has value I assume (haven't looked at patent expiration dates in awhile) but the buyer of the IP doesn't want the AOLS ticker -- it's not an asset because it has BAGGAGE in the form of stock owned by someone else. If they go public, they will get a new shell. A ticker with issued stock owned by someone else is not an asset -- it's a liability.

Nobody is "putting anything into this ticker." So you see that it's not ME that's putting up false information.

I would like to know who owns the patents now to see if they try to develop something, but that doesn't mean anything to AOLS shareholders because they got left behind. They are holding a bag of nothing.

Am I understood better now? If not, oh well, that's not my problem.

[Werbe]

AIOLOS (Aeolus) was the divine keeper of the winds and king of the mythical, floating island of Aiolia (Aeolia). He kept the violent Storm-Winds locked safely away inside the cavernous interior of his isle, releasing them only at the command of greatest gods to wreak devastation upon the world.

The hero Odysseus once visited Aiolos' isle and was entrusted with a bag containing all of the Storm-Winds to ensure a safe voyage home. However, during the trip, the hero's greedy companions opened the bag in a search for gold and the escaping winds carried their ship all the way back to Aiolos' shore.

The Winds were often conceived of as horse-shaped gods or spirits, and as such Aiolos was titled Hippotades, "the reiner of horses," from the Greek words hippos ("horse") and tadên ("reined in tightly").

Homer's wind-god Aiolos bears many similarities to Hesiod's Ouranos (Uranus)--both are described as having six sons and daughers joined in wedlock, and both kept a group of storm-spirits locked behind a threshold of bronze. In the case of Ouranos, the twelve children were the Titan-gods, and the storm-gods were the Hekatonkheires (Hecatoncheires) and Kyklopes (Cyclopes) in Tartaros.

Aiolos also resembles Astraios (Astraeus), Hesiod's father of the winds and stars. Stesichorus seems to confirm this connection when he describes Aiolos Hippotades as the cousin of Iris Thaumantias ("the wondrous rainbow") for Astraios was a son of Eurybia and Iris a daughter of Eurybia's brother Thaumas.

It should also be noted that the Greek words aiolos ("glittering"), aiolokhros ("spangled"), and astraios ("starry") were all adjectives applied to the starry night-sky (ouranos)..

[Werbe]

Hmm I am going by Waybackmachine and I see same info on site I linked as from March and July and up until October of this year. You put in same address and it shows you coming soon as of now?? Please explain your info so you can be UNDERSTOOD better.

You can say whatever you want, PR shows they went outside of court system. That would be called BANKRUPTCY? That would give the ticker a Q? This ticker is just behind in filings, no dreaded Q? Hmm read the PR again. They use assets to pay off all owed and shareholders might be left with something. If they are left with something that can be made into a company, that would be okay to spinoff?? Debts are paid etc.. Or even if the buyers of the assets of this ticker and anything tied to it decide to put something into this ticker??

I know the IP is worth something, I read others DD so you would know the info I put up shows this.. ALso, do your own DD. Find your own news you are looking for, I saw you put up misleading info, I corrected it. YOURE WELCOME!!

[GetSeriousOK]

website changed in July, not last month.

Aeolus didn't go through the court system because that costs money and they had none. They simply threw in the towel. Creditors didn't go through the court system because they knew that would result in LESS net recovery, not more.

Unless Aeolus tries to spin off something to hide the IP from the creditors. THAT would end up in court.

The IP is worth something. The "heads up" I am looking for is news about where the IP ends up. Nothing else interesting here, because no matter what happens, AOLS shares are worthless IMO, but thanks!

[Werbe]

Lol relax my man. I noticed the website change.. They did not go through the court system for a reason IMO, especially after seeing the website recent change I say something is up. Aeolus could be dead or could be alive under a new spinoff or even this ticker could be just a vehicle for a new company etc...

Also why would company website change in last month coinciding with new volume?? That is strange imo, worthy of a buy for some. Regardless, I just wanted 2 give u heads up. Good Luck GetSeriousOK.

[GetSeriousOK]

What is your point? are you trying to say that Aeolus is rising from the ashes? Where's the proof?

you read this PR I assume:

https://www.marketscreener.com/AEOLUS-PHARMACEUTICALS-I-141076/news/Aeolus-Pharmaceuticals-Inc-Aeolus-Announces-Commencement-of-Assignment-for-the-Benefit-of-Credit-26219280/

I said "the website is gone" because it was still online up until the middle of July, with old outdated information like optimistic talk about BARDA.... then suddenly it disappeared, so I posted to that effect.

WHOIS lists the domain as active, renewed in May 2018 with an owner in Toronto... then, instead of updating it, someone removed it in July.

Sorry, Aeolus is dead. Better off buying lottery tickets, LITERALLY.

https://www.otcmarkets.com/stock/AOLS/overview

[Werbe]

That is wrong website link.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145597312

[Werbe]

Stuart my man, I believe they either are still alive and kicking or they spunoff/RM this. Volume coming out of nowhere makes me think you are correct with this bounce. Good luck Stuart.

[Werbe]

No problem man. They do owe money etc but I found it strange they did this out of court. No Q added to ticker.. Anyways there is this also... The website listed on otcmarkets is wrong. Here is there website per last official PR. http://www.aeoluspharma.com/

Now check out the below snapchat from the wayback machine from October 20th this year... Strange?

https://web.archive.org/web/20181020013932/http://www.aeoluspharma.com/

[Stuart_Stardust]

Hey buddy, thanks for the heads up. I'm waiting for serious volume here, pretty sure we have a bounce in the making.

[Werbe]

Also Stuart, patents in Japan and EU.. Michael J Fox foundation gave them a grant.. I linked my earlier post with what I uncovered here. Ok bye Stuart.

MISSION VIEJO, CA --(Marketwired - April 18, 2016) - Aeolus Pharmaceuticals (OTCQB: AOLS)

AEOL 11114 Is Subject of Michael J Fox Foundation Research Grant Program
Efficacy Demonstrated in Two Parkinson's Disease Models
IND Filing for Parkinson's Disease Targeted for First Half of 2017
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that the European Patent Office issued patent number 2625180 covering the composition of matter for its oral Parkinson's disease drug AEOL 11114. The Company also announced that a patent for AEOL 11114 has been allowed in Japan. AEOL 11114 has demonstrated neuro-protective activity in models of Parkinson's disease and other indications. The compounds were invented by Brian J. Day, PhD at National Jewish Health and Manisha Patel, PhD at the University of Colorado, Anschutz Medical Campus, Department of Pharmaceutical Sciences in collaboration with Aeolus Pharmaceuticals and under two research grants from the Michael J. Fox Foundation for Parkinson's disease. Aeolus has obtained worldwide, exclusive licenses to develop the compounds from National Jewish Health and the University of Colorado.

Aeolus is currently working on optimization of the AEOL 11114 manufacturing process and formulation. Upon completion of this work, IND-enabling safety and toxicology studies are planned to begin in the third quarter of 2016. Aeolus plans to file an IND for the treatment of patients with Parkinson's disease during the first half of 2017. The Company intends to pursue a partner with clinical development expertise in this indication to initiate clinical studies.

Preclinical studies funded by the Michael J. Fox Foundation in two models of Parkinson's disease demonstrated that AEOL 11114 reduced oxidative stress and damage, mitigated dopamine depletion, prevented loss of nigrostriatal dopaminergic neurons, the most important neuropathological feature of Parkinson's disease, and improved Parkinson's disease-like motor deficits. Additional studies funded by the Fox Foundation have shown that AEOL 11114 exhibited drug-like characteristics with a favorable pharmacokinetic profile, oral bioavailability, metabolic stability and brain penetrance, and a safety profile amenable for long-term dosing.

"AEOL 11114 has exciting potential as a Parkinson's disease treatment given its mechanism of action, its pharmacokinetic and safety profile and the significant efficacy it has demonstrated in two widely used animal models of the disease," stated John L. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "We now have active development programs for three compounds in seven indications. Our Parkinson's program in AEOL 1114 joins our development programs for AEOL 10150 in Pulmonary Acute Radiation Syndrome, Radiation Therapy for Cancer and Idiopathic Pulmonary Fibrosis. In addition, we are currently conducting pre-clinical studies in our infectious disease compound, AEOL 20415, with the intention of filing an IND in 2017. With our substantial US government development contract for AEOL 10150 in Acute Radiation Syndrome, the planned human clinical trials in IPF and radiation oncology and the new compounds in development, the Company never been more diversified or better capitalized."

Parkinson's disease is a disorder of the central nervous system that results from the loss of cells in various parts of the brain, including the substantia nigra. The substantia nigra cells produce dopamine, which transmits signals within the brain that allow for coordination of movement. Loss of dopamine causes neurons to fire without normal control, reducing a patient's control of their movement. It is estimated that more than one million people in the United States and five million people worldwide are affected by Parkinson's disease.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140947622

[Werbe]

Hey Stuart, volume picked up out of nowhere a few days ago.. This is strange ticker.. US government dumped mega into the compounds that were worked on here but abandoned it and it was without funds. News in march led the ticker 2 be crushed but these compounds and the work behind them should get mega money. They did an out of court settlement so IMO, they wanted the ticker alive. You never know what could happen here, but I am stupid rookie so do not take my word 4 it. I grabbed .005s awhile back because I liked what I saw.

MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to enter into a General Assignment agreement with John D. McLaughlin, Jr., Esq. as the Assignee of all of Aeolus' remaining assets. To this effect, Aeolus has transferred its assets to the Assignee whose contractual duty is to liquidate these assets and distribute any proceeds to creditors. If the recovered value of these assets is not greater than the liabilities of Aeolus, there will not be any residual value for stockholders. In connection with the Assignment, Aeolus will discontinue the development of its compounds and all other operations.

[Stuart_Stardust]

A serious bounce today?

[Coniba]

Yeah def worth a flyer. Probably catching some tax loss selling through CDEL. We shall see

[JPerdue2]

Interesting day here... Added a small starter as well

[Coniba]

bought a few on the volume AOLS 200M A/S 54m FLOAT

[mick]

http://www.barchart.com/technicals/stocks/aols

[TAKURI]

AOLS

AEOLUS PHARMACEUTICALS INC COM AOLS: OTC Pink - Current Information
Healthcare : Pharmaceuticals
Snapshot
Charts
News
Options
Analyst Research
Fundamentals
Earnings
Insider Activity
Last Price Today’s Change Bid (Size) Ask (Size) Day’s Range Volume
0.0061 +0.0012 (+24.49%) 0.0049 x170,000 0.0069 x10,000 0.0049 - 0.0061 237,655

OTC Pink - Current Information Delayed Quote Last Trade as of 12:35 PM ET 6/6/18
Insider Activity Ownership
HOLDINGS SUMMARY
Holdings
Total Number of Shares Held 97,037,244
Large Block Owners 2
Percent Shares Owned 63.80%
Percent Change in Ownership --

63.70% Investment Managers
0.10% Strategic Entities
36.20% Non-Institutional
Mouseover legend for more detail.
Regional Holdings
North America 63.80%
Europe 0.00%
South/central America 0.00%
Monthly Share Rotation
Type Number of Shares Value of Change Shares Outstanding
Buyers 6/5/18 -- -- --
Sellers 6/5/18 -- -- --

TOP OWNERS
Concentration of Shares Held

63.80% Top Owners
63.80% Top 50 Owners
63.80% Top 20 Owners
63.80% Top 10 Owners

36.20% Other Owners
Other Owners


Name Shares Held Position Value % of Total
Holdings Outstanding
Shares Owned Investment Style
McManus (John L) 105.3 K $20.0 K 0.11 2.16% N/A
Xmark Opportunity Partners, L.... 96.9 M $18.4 M 99.89 1,985.19% N/A

[mick]

Aeolus Pharmaceutica (AOLS)
0.004 ? -0.0012 (-23.08%)
Volume: 53,170 @ 2:31:09 PM EDT ET
Bid Ask Day's Range
0.004 0.006 0.004 - 0.005
AOLS Detailed Quote

[GetSeriousOK]

The website is gone.

I dumped all my shares so I'm not going to get any notification -- if anyone still holding shares gets a notification from the company when the liquidation is done, please post it here. Much appreciated.

[mick]

http://www.barchart.com/detailedquote/stocks/AOLS

[mick]

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
[phone], [phone] fax

[mick]

Termination of Registration of a Class of Security Under Section 12(g) (15-12g) "Edgar (US Regulatory)" - 12/22/2017 4:53:22 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/14/2017 5:09:19 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/15/2017 5:59:03 PM

[mick]

Aeolus Pharmaceutica (AOLS)
0.0045 ? -0.002 (-30.77%)
Volume: 28,270 @ 12:11:11 PM EDT ET
Bid Ask Day's Range
0.0001 0.27 0.0045 - 0.0058
AOLS Detailed Quote

[TAKURI]

Aeolus Pharmaceutical, Inc.at LD Micro Invitational Conference-JUNE 4,2014

Overview

Aeolus Pharmaceuticals, Inc. is developing its lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure (“Lung-ARS” and “DEARE”). The Company’s development work is funded under a five year, $118 million, cost-plus contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. BARDA is the Federal agency in charge of contracting for advanced development of drugs to treat radiological, biological and chemical threats for the civilian population. BARDA also manages the $2.8BB Special Reserve Fund for the purchase of these drugs for the U.S. Strategic National Stockpile.

Under the contract, Aeolus expects to meet the requirements for a pre-Emergency Use Authorization filing for AEOL-10150 in 2014. An Emergency Use Authorization (“EUA”) is a finding by the U.S. FDA that allows the use of unapproved drugs in the event of an emergency. BARDA has historically made the majority of its purchases for the stockpile using the EUA prior to FDA approval.

AEOL-10150 has demonstrated survival advantage in multiple animal models for Lung-ARS. The Company is currently conducting an efficacy study in non-human primates that will be complete in Q3 2014. Because of the nature of lethal radiation studies, no human efficacy studies are possible or required for FDA approval for Lung-ARS.

Aeolus also receives funding from the National Institutes of Health for the development of AEOL-10150 as a treatment for exposure to chemical gas (e.g., mustard and chlorine) and nerve agents (e.g., sarin and soman). The development work under these programs has positioned AEOl-10150 as a treatment for multiple biodefense threats, making it an attractive candidate for potential procurement into the Strategic National Stockpile.

AEOL-10150 has been tested in two Phase I human safety studies with no adverse events and no maximum tolerated dose.

Aeolus is leveraging the significant investment from the US Government to develop AEOL-10150 as a combination therapy for patients receiving radiation treatment for cancer. One million patients each year receive radiation therapy for solid tumors but the effectiveness of this treatment is often compromised by side effects that cut short treatment or limit the dose of therapeutic radiation delivered.

[TAKURI]

https://www.bloomberg.com/quote/AOLS:US

[TAKURI]

WEAK SELL https://www.barchart.com/stocks/quotes/AOLS

[TAKURI]

AOLS....very very thin SS !$!$!

[TAKURI]

GMA !$!$!$!

[makinezmoney]

$AOLS: Upside movement today..... hitting $0.0061


Let see it get back to $0.10/sh before that DUMP went down.

Looks like a Nice VALUE PLAY HERE


GO $AOLS

[Werbe]

If you have something different, please post them. Also, going by the last annual, which was an amended version of 2016, I see beneficial owners of at least 72%, 63% which were controlled by insiders through proxies?? These numbers are usually inflated slightly from any warrants added in the total. Info below.

Also I do not get your question? I do not see float numbers updated anywhere showing different? I go by assumption no restricted came off. That was last known facts. If you have different float numbers show them. I do not mind being wrong but I need proof.

What year end statement?? I see no filings showing this, please link me 2 2017 annual please?

I could care less about institutional owners in the OTC, especially this low, I would think some would be embarrassed 2 have that badge LOL.

[GetSeriousOK]

that was as of 2/17/2017, but as of 12/31/2017, the O/S and float are identical -- there are no insider or institutional holdings.

The one institutional holder, Intellectus, sold out in 2017. Read their year-end statement.

Sorry.

[GetSeriousOK]

don't think so, but, whatever.

[Werbe]

Share Structure as of 02/17/2017

Authorized Shares 200,000,000

Outstanding Shares 152,085,825

Float 53,784,744


Last news from March of this year killed the ticker .

"AEOL 10150 has been safe and well tolerated in 40 ALS patients and 9 healthy subjects and has demonstrated significant efficacy in animal models developed by BARDA and NIH as a broad spectrum medical countermeasure against radiation, sulfur mustard, soman, chlorine and phosgene gas exposure," said John L. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "We are grateful for NIH's continued support and commitment to move AEOL 10150 to approval in these indications. Aeolus and the US Government have invested more than $100 million to date and there are currently no treatments to address these very real threats that our country faces today. We also appreciate the collaboration, clear guidance and direction we have received from the FDA Division of Medical Imaging Products in establishing a pathway for approval under the Animal Rule."

About Acute Radiation Syndrome (ARS) and the Delayed Effects of ARS

AEOL 10150 is currently the only treatment in advanced development for Lung ARS. Statistically significant improvement in survival in both NHP and mouse models of Lung ARS have been demonstrated at HED's that have been safe and well tolerated in human safety studies. In June 2017, AEOL 10150 was granted Fast Track designation for Lung ARS by the FDA, and a special protocol assessment to reach agreement on the design of a pivotal ("adequate and well designed") study in the NHP will be submitted to the FDA shortly.

https://finance.yahoo.com/news/aeolus-aeol-10150-safe-well-120000983.html

On top of that AEOL 10150, they also created two more compounds, one which already has patents in Europe and Japan.

AEOL 11114 Is Subject of Michael J Fox Foundation Research Grant Program

Also this from 1 year ago on their AEOL 20415 compound..

Results from a new animal study show that Aeolus Pharmaceuticals’ anti-microbial compound, AEOL 20415, may protect the lungs from infections in cystic fibrosis (CF).

In the study, conducted in a mouse model of CF and led by Brian Day, PhD, vice chair of research at National Jewish Health, AEOL 20415 showed to be a potential treatment for antibiotic-resistant bacteria.

“This study confirms previous in-vitro studies indicating that AEOL 20415 is unique because it augments the body’s natural host defense system for fighting bacterial infection while limiting inflammation,” Day said in a press release.

“Currently available anti-inflammatory drugs work by suppressing the immune system, which can be counterproductive during active infection. AEOL 20415 has demonstrated efficacy in killing drug resistant clinical strains of Burkholderia cepacia and Pseudomonas aeruginosa isolated from cystic fibrosis patients and improving bacterial clearance while diminishing lung inflammation.” Day added.

Now about the insiders that were here, I am not sure what is going on anymore... Most had ties to the National Jewish Health. Very reputable... https://www.nationaljewish.org/home

Now on NationalJewish webpage, under startup companies, they show Aeolus Pharma.... They have direct ties with Aeolus as shown below.

[GetSeriousOK]

Website looking rough.

http://www.aeoluspharma.com/ is just an outline, and none of the links work.

http://www.aolsrx.com/ is a 404 not found.

I think the fat lady is singing.

[PBGoodwill]

http://www.credenceresearch.com/report/radiation-toxicity-radiation-sickness-acute-radiation-syndrome-treatment-market

https://journalhealthcare.com/118733/radiation-toxicity-market-pipeline-2018-drug-product-description-molecule-type-and-route-of-administration/

[mick]

$AOLS STILL IN THERE

[mick]

http://www.stockscores.com/charts/charts/?ticker=AOLS

[jimbob4stocks]

Let me know what you find

[GetSeriousOK]

I am going to try and discover what entity, if any, buys the IP of the compounds. I would follow that company and buy their stock if they are publicly traded.

Best of luck!